Valuation: Hanall Biopharma Co., Ltd.

Capitalization 2,641B 1.79B 1.54B 1.44B 1.34B 2.49B 163B 2.68B 16.54B 6.52B 77.55B 6.72B 6.58B 283B P/E ratio 2025 *
1,433x
P/E ratio 2026 * 300x
Enterprise value 2.63B 1.78M 1.54M 1.43M 1.33M 2.48M 162M 2.67M 16.46M 6.49M 77.17M 6.69M 6.55M 282M EV / Sales 2025 *
16.9x
EV / Sales 2026 * 14.9x
Free-Float
59.17%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+9.59%
1 week+2.97%
Current month+18.86%
1 month+23.96%
3 months+55.92%
6 months+77.47%
Current year+18.86%
More quotes
1 week 46,100
Extreme 46100
55,000
1 month 41,700
Extreme 41700
55,000
Current year 41,700
Extreme 41700
55,000
1 year 24,000
Extreme 24000
57,100
3 years 15,090
Extreme 15090
57,100
5 years 12,450
Extreme 12450
57,100
10 years 10,450
Extreme 10450
57,100
More quotes
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2021
Chief Executive Officer 54 28/03/2023
Chief Tech/Sci/R&D Officer 55 -
Director TitleAgeSince
Director/Board Member 62 -
Chairman 66 29/07/2015
Director/Board Member 50 -
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+9.59%+2.97%+32.99%+214.20% 1.79B
+0.53%-2.37%+43.09%+194.99% 930B
-0.41%+6.98%+48.72%+28.81% 527B
-1.11%-2.60%+24.94%+43.67% 379B
-0.53%+1.26%+29.94%+17.78% 371B
-0.56%-0.98%+29.53%+22.43% 292B
+0.10%+1.72%+29.78%+37.03% 276B
-1.93%-1.54%+11.14%+0.04% 270B
-3.60%-0.61%-31.65%-21.34% 268B
+0.12%+1.32%+21.43%+24.97% 178B
Average +0.22%+1.06%+23.99%+56.26% 349.27B
Weighted average by Cap. -0.55%+0.51%+29.07%+67.43%
See all sector performances

Financials

2025 *2026 *
Net sales 155B 105M 90.8M 84.53M 78.69M 147M 9.56B 158M 972M 383M 4.56B 395M 387M 16.65B 176B 119M 103M 95.66M 89.06M 166M 10.82B 178M 1.1B 434M 5.16B 447M 438M 18.84B
Net income 1.98B 1.34M 1.16M 1.08M 1M 1.87M 122M 2.01M 12.4M 4.89M 58.15M 5.04M 4.93M 212M 8.98B 6.09M 5.25M 4.89M 4.55M 8.48M 553M 9.12M 56.25M 22.18M 264M 22.85M 22.38M 963M
Net Debt -12.92B -8.77M -7.56M -7.04M -6.55M -12.2M -796M -13.13M -80.97M -31.93M -380M -32.89M -32.21M -1.39B -17.75B -12.04M -10.38M -9.67M -9M -16.76M -1.09B -18.03M -111M -43.84M -521M -45.17M -44.24M -1.9B
More financial data * Estimated data
Logo Hanall Biopharma Co., Ltd.
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.
Employees
304
More about the company
Date Price Change Volume
16/01/26 52,000.00 +9.59% 1,921,051
15/01/26 47,450.00 +1.39% 343,492
14/01/26 46,800.00 -4.29% 554,817
13/01/26 48,900.00 -1.91% 429,462
12/01/26 49,850.00 -1.29% 381,479

End-of-day quote Korea S.E., January 15, 2026

More quotes
Trader
Investor
Global
Quality
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
52,000.00KRW
Average target price
42,800.00KRW
Spread / Average Target
-17.69%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A009420 Stock